TMCI Stock Fair Value – TREACE MEDICAL CONCEPTS Reports 40% Increase in Revenue for Second Quarter of FY2023

August 16, 2023

☀️Earnings Overview

TREACE MEDICAL CONCEPTS ($NASDAQ:TMCI) reported total revenue of USD 42.0 million for the second quarter of FY2023 ending June 30 2023, which represented a 40.0% increase year-over-year from the same period in FY2022. Net income for the quarter improved from -17.2 million in the previous year to -12.3 million.

Analysis – TMCI Stock Fair Value

GoodWhale has conducted an in-depth analysis of the fundamentals of TREACE MEDICAL CONCEPTS, a medical diagnostics company. Through our proprietary Valuation Line, we have determined the intrinsic value of the company’s stock to be $29.8. This means that the current market price of $20.1 is undervalued by 32.5%, presenting a potential buying opportunity for savvy investors. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis
  • About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for TMCI. More…

    Total Revenues Net Income Net Margin
    166.97 -42.27 -25.3%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for TMCI. More…

    Operations Investing Financing
    -38.44 -160.77 109.71
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for TMCI. More…

    Total Assets Total Liabilities Book Value Per Share
    249.64 99.68 2.45
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for TMCI are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    53.2% -22.3%
    FCF Margin ROE ROA
    -31.3% -15.1% -9.3%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items

  • Peers

    The company has a strong product portfolio and a wide geographical presence. The company is facing stiff competition from its rivals Pace Medical Inc, Tenon Medical Inc, and EMvision Medical Devices Ltd.

    – Pace Medical Inc ($OTCPK:PMDL)

    EMvision Medical Devices Ltd is a medical device company that develops, manufactures, and markets non-invasive brain scanning devices. The company’s products include the EMvision Neuro-Monitor, which is used for the detection and monitoring of seizures, and the EMvision Glioma Scanner, which is used for the diagnosis and treatment of brain tumors. The company was founded in 2006 and is headquartered in Sydney, Australia.


    TREACE MEDICAL CONCEPTS reported impressive financial results for the 2nd Quarter of FY2023, with total revenue reaching USD 42.0 million – a 40.0% increase from the same period in the previous year. Net income increased to USD -12.3 million, a significant improvement from the -17.2 million reported in the 2nd quarter of FY2022. Investors should take note of the strong revenue growth and the improved net income, which suggest that TREACE MEDICAL CONCEPTS is well-positioned for further success.

    Recent Posts

    Leave a Comment